

1 **Predicting 30-day mortality in patients with Sepsis; an exploratory**
2 **analysis of process of care and patient characteristics**

3 Miriam Sanderson¹ mzymis@exmail.nottingham.ac.uk

4 Dr Marc Chikhani ^{2,3} marc.chikhani@nottingham.ac.uk

5 Esme Blyth ⁴ eblyth1@sheffield.ac.uk

6 Sally Wood ² sally.wood@nuh.nhs.uk

7 Prof Iain K Moppett ^{2,3} iain.moppett@nottingham.ac.uk

8 Dr Tricia McKeever ⁵ tricia.mckeever@nottingham.ac.uk

9 Dr Mark J R Simmonds ² mark.simmonds@nuh.nhs.uk

10 1. School of Medicine, University of Nottingham

11 2. Nottingham University Hospitals NHS Trust

12 3. Division of Clinical Neuroscience, Faculty of Medicine and Health Sciences, University
13 of Nottingham

14 4. Sheffield Teaching Hosptials NHS Foundation Trust

15 5. Epidemiology and Public Health, Faculty of Medicine and Health Sciences, University of
16 Nottingham

17 All correspondence to: Marc.chikhani@nottingham.ac.uk

18

19

20

21

22 **Keywords**

23 Sepsis, mortality, survival, prediction, epidemiology

24 **Ethics, consent and permissions**

25 Observational quality improvement project prospectively reviewed by the Nottingham
26 University Hospitals NHS Trust Research and Innovation Committee in 2004. Permission
27 granted for data collection and reporting of results by the Caldicott Guardian. The need
28 for ethical review was waived. The project was registered with the audit office,
29 registration number 2890. All patient identifiable metrics removed from data prior to
30 analysis.

31 **Declarations of interest**

32 MJRS was an unpaid member of the NICE Sepsis (CG51) Guideline Development Group.
33 All other authors, no conflicts to declare.

34 **Word Count: 2797 (including abstract, tables, headings and parentheses)**

35 **Abstract – Word Count 243**

36 **Background:** Sepsis represents a significant public health burden, costing the NHS
37 £2.5 billion annually, with 35% mortality in 2006. The aim of this exploratory study was
38 to investigate risk factors predictive of 30-day mortality amongst patients with sepsis in
39 Nottingham.

40 **Methods:** Data was collected prospectively from adult patients with sepsis in
41 Nottingham University Hospitals NHS Trust as part of an on-going quality improvement
42 project between November 2011 and March 2014. Patients admitted to critical care with
43 the diagnosis of sepsis were included in the study. 97 separate variables were
44 investigated for their association with 30-day mortality. Variables included patient
45 demographics, symptoms of SIRS (systemic inflammatory response syndrome), organ
46 dysfunction or tissue hypoperfusion, locations of early care, source of sepsis and time to
47 interventions.

48 **Results:** 455 patients were included in the study. Increased age (adjOR=1.05
49 95%CI=1.03-1.07 $p<0.001$), thrombocytopenia (adjOR=3.10 95%CI=1.23-7.82
50 $p=0.016$), hospital-acquired sepsis (adjOR=3.34 95%CI=1.78-6.27 $p<0.001$), increased
51 lactate concentration (adjOR=1.16 95%CI=1.06-1.27 $p=0.001$), remaining hypotensive
52 after vasopressors (adjOR=3.89 95%CI=1.26-11.95 $p=0.02$) and mottling (adjOR=3.80
53 95%CI=1.06-13.55 $p=0.04$) increased 30-day mortality odds. Conversely, fever
54 (adjOR=0.46 95%CI=0.28-0.75 $p=0.002$), fluid refractory hypotension (adjOR=0.29
55 95%CI=0.10-0.87 $p=0.027$) and being diagnosed on surgical wards (adjOR=0.35
56 95%CI=0.15-0.81 $p=0.015$) were protective. Treatment timeliness were not significant
57 factors.

58 **Conclusion:** Several important predictors of 30 day mortality were found by this
59 research. Retrospective analysis of our sepsis data has revealed mortality predictors
60 which appear to be more patient related than intervention specific. With this information,
61 care can be improved for those identified most at risk of death.

62 **Introduction**

63 Sepsis is defined as life threatening organ dysfunction resulting from a dysregulated host
64 response to infection [1] and represents a significant burden to UK healthcare. Between
65 5.1% and 7% of all deaths in the UK are associated with sepsis [2], costing the NHS
66 £2.5 billion annually [3]. Sepsis is the second highest cause of mortality in the UK, with
67 between 36,000 to 64,000 people dying per year [4].

68 Following “unacceptably high” [5] mortality rates from sepsis (and associated historical
69 terms severe sepsis), the *Surviving Sepsis Campaign* set out to standardise treatment
70 through protocols. Early Goal Directed Therapy (EGDT) detailed interventions for treating
71 patients with sepsis and their time-frame. After multiple permutations of the guidelines,
72 and their latest revision in 2016, the current recommendations include time critical
73 administration of antimicrobial therapy and cardiovascular resuscitation (target within 1
74 hour and 3 hours respectively) [1]. Initial studies showed improved in hospital mortality
75 for septic patients treated with EGDT [6]. However, subsequent research including three
76 large clinical trials and their associated meta-analysis, have shown no significant
77 improvement in patient outcome when using EGDT [7–10], undermining initial treatment
78 strategies.

79 Despite the overwhelming burden of the disease, slow progress on treatment strategies
80 has prompted calls for further research into sepsis. In particular, more knowledge is
81 required of the factors that increase the risk of death from sepsis, in order to guide
82 treatment protocols and delivery of care, and ultimately reduce sepsis-associated
83 mortality. This exploratory study aims to investigate patient factors, signs, symptoms
84 and process of care and their association with 30 day mortality.

85

86 **Methods**

87 Data was prospectively recorded between November 2011 and March 2014 on adult
88 patients with sepsis presenting Nottingham University Hospitals NHS Trust, as part of an
89 ongoing quality improvement project in managing sepsis since 2005. Patients were
90 identified as those admitted to the critical care department including the intensive care
91 unit, and both the medical and surgical high dependency units with the diagnosis of
92 sepsis [11]. Inclusion criteria were based on the penultimate consensus definition for
93 severe sepsis, with presence of two or more signs of the systemic inflammatory response
94 syndrome (SIRS) and one or more sign of organ dysfunction or tissue hypoperfusion
95 with a background of proven or suspicion of infection. Confirmatory blood culture was
96 not an inclusion criterion. Patients were excluded if they were transferred from another
97 hospital with pre-existing sepsis.

98 A dedicated sepsis team collected the information using a previously validated data
99 collection tool [12]. Variables included patient demographics, symptoms of SIRS,
100 markers of organ dysfunction or tissue hypoperfusion, source of sepsis, locations of early
101 care, and time to interventions. These 97 variables were then assessed for association
102 with 30 day mortality, the primary outcome (online supplement Table E1). Data on 30
103 day mortality was collected routinely from the hospital administrative system, including
104 both hospital and community deaths. Time zero was the time of the initial symptom, sign
105 or indicator of organ dysfunction or tissue hypoperfusion due to severe sepsis.

106 Basic characteristics were obtained using summary statistics and univariate analyses.
107 Chi² and Fisher's exact test were used to assess categorical variables. Independent
108 samples t-test and Mann-Whitney test were used for continuous data, as appropriate.

109 A multi-variate model was built including all those variables that were significant
110 predictors of 30 day mortality ($p < 0.05$). Those variables that that were no-longer
111 significant were removed, then each non-significant variable was added individually to
112 the model and keeping significant variables. Likelihood-ratio test determined the

113 significance of categorical variables in terms of 30 day mortality. For all tests, a
114 significance level of $p < 0.05$ was used. All data was analysed in Stata (version 13)
115 The data collection was registered under the Nottingham University Hospitals Audit
116 Office, with the reference number 2890. Initial permission for data collection was
117 granted in 2004, with an institutional waiver for informed consent. For analysis, data
118 was anonymised, with all patient-identifiers removed from the database.

119 **Results**

120 455 patients were identified with severe sepsis, with 26.2% mortality. Age ranged from
121 17 to 95 and mean age was 64.0 years (standard deviation=16.6). 42% of patients were
122 female.

123 Following univariate analysis for association with 30 day mortality (Online table E1-E11),
124 fever ($>38.3^{\circ}\text{C}$) (OR=0.35 95%CI=0.23-0.55), (Table E2, additional file), sepsis from
125 skin infection (OR=0.34 95%CI=0.12-0.99), (Table E5, additional file), and not needing
126 inotropes within 6 hours (OR=0.36 95%CI=0.15-0.89), (Table E10, additional file), were
127 shown to be protective. Increased age (Table E1, additional file), hypothermia (core
128 temperature $<36^{\circ}\text{C}$) (OR=3.44 95%CI=1.83-6.45), (Table E2, additional file), altered
129 mental status (OR=1.88 95%CI=1.14-3.10), (Table E2, additional file), coagulation
130 abnormalities (OR=2.94 95%CI=1.00-8.61), (Table E3, additional file),
131 thrombocytopenia (platelet count $<100 \times 10^9/\text{L}$) (OR=2.85 95%CI=1.32-6.15), (Table
132 E3), mottling of the skin (OR=4.50 95%CI=1.55-13.08), (Table E3, additional file),
133 elevated serum lactate concentration (Table E8, additional file), remaining hypotensive
134 after vasopressors (OR=3.80 95%CI=1.53-9.40), (systolic blood pressure $<90\text{mmHg}$ or
135 mean arterial pressure $<70\text{mmHg}$) (Table E9, additional file) and hospital acquired
136 sepsis (symptoms first shown >24 hours after hospital admission with different
137 diagnosis) (OR=1.80 95%CI=1.11-2.94), (Table E11, additional file) were shown to
138 increase odds of 30 day mortality.

139 Multivariate analyses (Table 1) demonstrated increasing age (OR per year increase=1.05
 140 95%CI=1.03-1.07), thrombocytopenia (OR=3.10 95%CI=1.23-7.82), higher lactate
 141 value (OR per mmol increase=1.16 95%CI=1.06-1.27), remaining hypotensive after
 142 vasopressor treatment (OR=3.89 95%CI=1.26-11.95), hospital-acquired sepsis
 143 (OR=3.34 95%CI=1.78-6.27) and mottling (OR=3.80 95%CI=1.06-13.55) to be
 144 predictors of increased odds of 30 day mortality. In addition, fever (OR=0.46
 145 95%CI=0.28-0.75), being on a surgical ward at the time of sepsis presentation
 146 (OR=0.35 95%CI=0.15-0.81 and fluid refractory hypotension as defined by the 2008
 147 and subsequently 2012 Surviving Sepsis Campaign guidelines, (OR=0.29 95%CI=0.10-
 148 0.87) were shown to be protective against 30 day mortality. No process of care factors
 149 was significant in either univariate or multivariate analysis.

150 **Table 1: Multivariate logistic regression model indicating variables significantly**
 151 **associated with 30 day mortality**

Variable	OR^a	AdjOR*	95%CI^b	p-value
Age (per year)		1.05	1.03-1.07	<0.001
Temperature >38.3°C	0.35	0.46	0.28-0.75	0.002
Thrombocytopenia (<100x10⁹/L)	2.85	3.10	1.23-7.82	0.016
Hospital-acquired sepsis	1.80	3.34	1.78-6.27	<0.001
Lactate Value (per mmol/L)		1.16	1.06-1.27	0.001
Fluid Refractory Hypotension^c	0.60	0.29	0.10-0.87	0.027
Remain in Hypotensive State^{cd}	3.80	3.89	1.26-11.95	0.02
Surgical Ward at Time Zero	0.57	0.35	0.15-0.81	0.015
Mottling of the skin	4.50	3.80	1.06-13.55	0.04

152 ^a Odds Ratio

153 *Adjusted Odds Ratio- mutually adjusted for everything in the table

154 ^b95% Confidence Interval

155 ^c Persistent systolic blood pressure <90mmHg or mean arterial pressure <70mmHg despite fluid
 156 resuscitation

157 ^d15 patients missing data

158

159 **Discussion**

160 Although there were a number of factors investigated, only 9 variables were predictors
161 of 30 day mortality, and none of these were process of care variables such as timeliness
162 of care, or seniority of doctor. Important predictors were increased age,
163 thrombocytopenia ($<100 \times 10^9$), hospital-acquired sepsis, increased serum lactate
164 concentration, remaining hypotensive following vasopressors and mottling of the skin, all
165 of which increased odds of 30 day mortality. In our data set, temperature $>38.3^\circ\text{C}$, fluid
166 refractory hypotension and being on a surgical ward were protective against 30 day
167 mortality. With the exception of fluid refractory hypotension proving significantly
168 protective, these variables are largely consistent with other research(13–15).

169 **Age**

170 There are two reasons why older age may be associated with increased mortality in
171 patients with sepsis. First, with increased age is associated with decreased lymphocyte
172 function, causing weakened immune responses [16]. This is compounded by poor
173 nutritional status and altered cytokine response [17]. The second possibility is that older
174 patients have more comorbidities (itself an independent risk factor for death from sepsis
175 [18]).

176 **Temperature $>38.3^\circ\text{C}$**

177 Fever may be associated with improved outcomes for both pathophysiological and care-
178 process reasons. Fever has been associated with better outcomes in other studies
179 including the *FACE Study Group* [13], which found the odds ratio for mortality associated
180 with fever (37.5°C - 38.4°C) was 0.45 ($p=0.014$), almost identical to the odds ratio found
181 in this research. Fever enhances immune cell activity, with increased cytokine production
182 [19], and inhibits pathogen growth, improving survival [13,20,21]. Additionally, as a
183 widely recognised symptom and sign of sepsis even amongst non-healthcare
184 professionals, fever may result in earlier recognition and faster treatment, which may in
185 turn be beneficial for survival.

186

187 **Thrombocytopenia (<100x10⁹/L)**

188 The finding that thrombocytopenia was significantly associated with 30 day mortality in
189 septic patients, with an odds ratio of 3.1, is supported by other research [22–24]. *Lee et*
190 *a/* found that platelet count was significantly higher in survivors of sepsis than those who
191 died (194+/-27x10⁹/L versus 97+/-18x10⁹/L, $p<0.004$), concluding also that
192 thrombocytopenia is an independent risk factor for mortality in septic patients. Indeed
193 low platelet count is included as a marker of poor prognosis in the SOFA score
194 (sequential organ failure assessment), used to assess severity of organ failure [25].

195 **Lactate value**

196 Elevated lactate is either a marker of reduced global perfusion and tissue hypoxia with
197 associated anaerobic cellular respiration or reduced hepatic clearance of lactate [26].
198 Previous studies have shown a linear relation between increased lactate and increased
199 mortality [14], in accordance with our finding that increased serum lactate is a marker
200 poor prognosis.

201 **Mottling of the skin**

202 Mottling (*livedo reticularis*) is caused by peripheral blood vessel constriction [15].
203 Previous studies have demonstrated an association between skin mottling and mortality
204 [15,27]. One theory suggests that mottling reflects microvascular abnormalities,
205 associated with organ dysfunction from microvascular shunting and hypoperfusion, and
206 therefore increased mortality from multiple organ failure.

207 **Fluid refractory hypotension (septic shock)**

208 In this study, the mortality rate of patients with septic shock at 30 days was 23.9%,
209 which is at the lower end of previous mortality estimates (22%-50%(28,29)). However,
210 these studies above do not distinguish between patients who did not respond to
211 vasopressor therapy, found to increase odds of 30 day mortality (see below), and

212 patients who did respond. Therefore, the difference in observed mortality rates may be
213 explained by the proportion of patients who remained hypotensive after receiving fluid
214 and subsequent vasopressors. Another plausible argument of the apparently protective
215 characteristic of septic shock is that it may represent the beneficial effect of expedient
216 transfer of patients into critical care to receive vasopressor therapy, which is otherwise
217 unavailable within the hospital. In this data set, 247 patients remained hypotensive after
218 fluid therapy, with a median average time of admission to critical care of 6 hours (inter
219 quartile range [IQR] 3.86-10 hours) compared to 97 patients who responded to fluid with
220 a median average admission time of 7 hours (IQR 4.25-14.3 hours). The wide range of
221 times and presence of outliers; fluid refractory 0-80 hours, and fluid responsive 0-244
222 helps to explain why this demonstrated a trend towards statistical significance with
223 $p=0.0527$.

224 **Remaining hypotensive after vasopressor treatment**

225 Fluid and vasopressor refractory hypotension was associated with increased mortality. In
226 combination with the previous finding that fluid refractory hypotension was protective,
227 this may indicate that prognosis is only poor in patients with septic shock, who fail to
228 respond to vasopressors.

229 **Hospital-acquired sepsis**

230 The care of septic patients admitted to critical care from wards rather than emergency
231 departments seems to be less well established, leading to higher in-hospital mortality
232 [30]. This supports our findings of an increased 30 day mortality in patients diagnosed
233 with severe sepsis on wards rather than from emergency admission areas such as the
234 Emergency Department or acute admission unit. Additionally, comorbidity and reason for
235 hospital stay may itself cause higher mortality within this population.

236 **Patient on surgical ward at time of diagnosis of sepsis**

237 Diagnosis of sepsis in patients on a surgical ward was found to be associated with a reduction
238 in 30 day mortality. Surgical patients may have a source of sepsis more amenable to

239 source control through surgical management, such as debridement or drainage,
240 improving survival prospects compared to medical patients in whom source control is
241 impossible to achieve, for example in severe pneumonia. Additionally, as sepsis is a
242 known complication of surgery [31,32], it is also possible that clinicians are more
243 receptive of the signs and symptoms necessary to facilitate rapid diagnosis.

244 **Process of Care Factors**

245 Process of care factors, such as time delay to be seen, seniority of assessing clinician,
246 and time delay to intervention were not found to significantly affect 30 day mortality.
247 This contradicts much of the early research into sepsis care [6,33,34], which formed the
248 foundations of EGDT and subsequent sepsis care bundles. However, recent research
249 including a systematic review [10] of three large clinical trials [7–9] also found no
250 significance between mortality and EGDT. It also must be considered that the apparent
251 lack of significance between the process of care factors and 30-day mortality may be due
252 to the low variability of care provided at our institution following over a decade of service
253 improvement in the care of patients with sepsis. This has included hospital wide
254 screening systems, multi-specialty and multi-disciplinary education programs, audit and
255 performance related feedback by a dedicated sepsis team. Therefore, whilst these
256 process factors such as time to treatment may still be significant with large variation in
257 practice, this was not detectable in this study. This is reinforced by the recent findings of
258 Seymour and colleagues [35].

259 **Strengths and limitations**

260 Exclusion criteria were minimised, making the study population representative of
261 patients in Nottingham. As the fourth largest acute trust in the UK, the results of this
262 study are highly generalizable to the rest of the UK. Missing data was low and the study
263 took place in a real-world setting. Data collection was carried out by a trained and
264 dedicated sepsis team with over a decade of experience in using the data collection

265 tools. It is important to note that this sepsis team were not involved in treatment of
266 these patients.

267 Limitations of this study include the large number of tests carried out, increasing chance
268 of false positive findings. If Bonferroni correction was applied only those results with a p -
269 value of <0.0005 would be considered significant. This work was carried out as an
270 exploratory study and therefore further work with larger data sets would be required to
271 confirm the findings of interest. For the duration of this work, the historical penultimate
272 sepsis definitions were used [11]. Although the term severe sepsis is no longer used and
273 the definition of septic shock has changed, it is felt that the results of this study are still
274 applicable as the core disease processes underpinning the definition have not changed.

275 It is important to realise a significant limitation of this study is the apparent selection
276 bias involved in patient identification of only those admitted to critical care areas with
277 the diagnosis of sepsis. This risks omitting a group of patients who were treated
278 appropriately with good response demonstrating early resolution of organ dysfunction.
279 However, this method of identification yields similar numbers compared to previous work
280 at Nottingham University Hospitals NHS Trust [12], this may be explained by evolving
281 practice in terms of managing patient acuity, disease severity and patient flow through
282 the hospital pathways such that a greater proportion of unwell patients are managed on
283 critical care than a decade ago.

284 **Conclusion**

285 In conclusion, this exploratory analysis presents the factors significantly associated with
286 30 day mortality in patients diagnosed with sepsis. Results suggest importance of patient
287 factors associated with mortality. Age, thrombocytopenia, remaining hypotensive after
288 vasopressor administration, hospital-acquired sepsis, increased serum-lactate
289 concentration and mottling all increased odds of 30 day mortality. Presentation on a
290 surgical ward, fever and septic shock were found to be protective. This paper highlights
291 some interesting risk factors associated with mortality from sepsis, indicating the

292 direction of further research, particularly into the seldom researched matter of hospital
293 acquired sepsis.

294 **References**

- 295 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et
296 al. The Third International Consensus Definitions for Sepsis and Septic Shock
297 (Sepsis-3). JAMA. 2016;315(8):801–10.
- 298 2. McPherson D, Griffiths C, Williams M, Baker A, Klodawski E, Jacobson B, et al.
299 Sepsis-associated mortality in England: an analysis of multiple cause of death data
300 from 2001 to 2010. BMJ Open. 2013;3(8):1–7.
- 301 3. Richards M. Sepsis management as an NHS clinical priority. Uk sepsis group.
302 2013.
- 303 4. Daniels R. Surviving the first hours in sepsis: getting the basics right (an
304 intensivist’s perspective). J Antimicrob Chemother. 2011;66(Supplement 2):ii11–
305 23.
- 306 5. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving
307 Sepsis Campaign guidelines for management of severe sepsis and septic shock.
308 Crit Care Med. 2004;32(3):858–73.
- 309 6. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. EARLY GOAL-
310 DIRECTED THERAPY IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK.
311 N Engl J Med. 2001;345(19):1368–77.
- 312 7. Mouncey PR, Osborn TM, Power GS, Harrison D a, Sadique MZ, Grieve RD, et al.
313 Trial of early, goal-directed resuscitation for septic shock. N Engl J Med.
314 2015;372(14):1301–11.
- 315 8. The ARISE Investigators and ANZICS Clinical Trials Group. Goal-Directed
316 Resuscitation for Patients with Early Septic Shock. N Engl J Med. 2014;371:1496–
317 506.
- 318 9. ProCESS Investigators. A randomized trial of protocol-based care for early septic

- 319 shock. *N Engl J Med.* 2014 May 1;2014(370):1683-93.
- 320 10. Angus DC, Barnato a E, Bell D, Bellomo R, Chong C-R, Coats TJ, et al. A
321 systematic review and meta-analysis of early goal-directed therapy for septic
322 shock: the ARISE, ProCESS and ProMISe Investigators. *Intensive Care Med.*
323 2015;41(9):1549–60.
- 324 11. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001
325 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.
326 *Intensive Care Med.* 2003;29(4):530–8.
- 327 12. Simmonds M, Hutchinson A, Chikhani M, Bewick T, Meyer J, Davies S, et al.
328 Surviving sepsis beyond intensive care : a retrospective cohort study of
329 compliance with the international guidelines. *J Intensive Care Soc.*
330 2008;9(2):124–7.
- 331 13. Lee BH, Inui D, Suh GY, Kim JY, Kwon JY, Park J, Tada K, Tanaka K, Ietsugu K,
332 Uehara K, Dote K. Association of body temperature and antipyretic treatments
333 with mortality of critically ill patients with and without sepsis: multi-centered
334 prospective observational study. *Critical care.* 2012 Feb 28;16(1):R33.
- 335 14. Mikkelsen ME, Miltiades AN, Galeski DF, Goyal M, Fuchs BD, Shah C V, et al.
336 Serum lactate is associated with mortality in severe sepsis independent of organ
337 failure and shock. *Crit Care Med.* 2009;37(5):1670–7.
- 338 15. Ait-Oufella H, Lemoinne S, Boelle PY, Galbois A, Baudel JL, Lemant J, et al.
339 Mottling score predicts survival in septic shock. *Intensive Care Med.* Springer-
340 Verlag; 2011;37(5):801–7.
- 341 16. Miller RA. The aging immune system: primer and prospectus. *Science.* 1996 Jul
342 5;273(5271):70.
- 343 17. Destarac LA, Ely EW. Sepsis in older patients: an emerging concern in critical care.

- 344 Advances in sepsis. 2001;2(1):15-22
- 345 18. Angus DC (Pitt), van der Poll T. Severe sepsis and septic shock. N Engl J Med.
346 2013;369(9):840-51.
- 347 19. Kushimoto S, Gando S, Saitoh D, Mayumi T, Ogura H, Fujishima S. The impact of
348 body temperature abnormalities on the disease severity and outcome in patients
349 with severe sepsis : an analysis from a multicenter , prospective survey of severe
350 sepsis. Crit Care. 2013;17(6):1-9.
- 351 20. Schortgen F. Fever in sepsis. Minerva anesthesiologica. 2012 Nov;78(11):1254-64.
- 352 21. Kluger MJ, Kozak W. The adaptive value of fever. Infect Dis Clin North Am.
353 1996;10(1):5520.
- 354 22. Lee KH, Hui KP, Tan WC. Thrombocytopenia in sepsis: a predictor of mortality in
355 the intensive care unit. Singapore medical journal. 1993 Jun;34(3):245-6.
- 356 23. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis-Associated Disseminated
357 Intravascular Coagulation and Thromboembolic Disease. Mediterr J Hematol Infect
358 Dis. 2010;2(3):1-18.
- 359 24. Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H.
360 Thrombocytopenia in the Sepsis Syndrome : Role of Hemophagocytosis and
361 Macrophage Colony-stimulating Factor. Am J Med. 1997;103(2):114-20.
- 362 25. Vincent J-L, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The
363 SOFA (Sepsis-related Organ Failure Assessment) score to describe organ
364 dysfunction/failure. Intensive Care Med. 1996;22(7):707-10.
- 365 26. Phypers B, Pierce JT. Lactate physiology in health and disease. Continuing
366 Education in Anaesthesia, Critical Care & Pain. 2006 Jun 1;6(3):128-32.
- 367 27. de Moura EB, Amorim FF, Silveira CD, Maia MO. Assessment of the mottling score
368 as a mortality predictor in critically ill patients. Critical Care. 2013 Mar

- 369 19;17(2):P217.
- 370 28. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence.
371 2014;5(1):4–11.
- 372 29. Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality Related to
373 Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New
374 Zealand, 2000-2012. *Jama*. 2014;311(13):1308–16.
- 375 30. Garcia-Diaz J, Traugott K, Seoane L, Pavlov A, Briski D, Nash T, Winterbottom F,
376 Dornelles A, Shum L, Sundell E. Severe Sepsis And Septic Shock: Worse Outcomes
377 Seen In Patients Transferred To ICU From Wards Compared To Emergency
378 Department. In A45. DIAGNOSTIC TECHNIQUES, MONITORING AND TECHNOLOGY
379 2013 May (pp. A1563-A1563). American Thoracic Society.
- 380 31. Moore LJ, Moore FA, Jones SL, Xu J, Bass BL. Sepsis in general surgery: a deadly
381 complication. *Am J Surg*. 2009 Dec;198(6):868–74.
- 382 32. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population
383 incidence of severe sepsis in Australian and New Zealand intensive care units.
384 *Intensive Care Med*. 2004;30(4):589–96.
- 385 33. Gaieski DF, Mikkelsen ME, Band R a., Pines JM, Massone R, Furia FF, et al. Impact
386 of time to antibiotics on survival in patients with severe sepsis or septic shock in
387 whom early goal-directed therapy was initiated in the emergency department. *Crit
388 Care Med*. 2010;38(4):1045–53.
- 389 34. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of
390 hypotension before initiation of effective antimicrobial therapy is the critical
391 determinant of survival in human septic shock. *Crit Care Med*. 2006;34(6):1589–
392 96.
- 393 35. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al.

394 Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. N
395 Engl J Med. 2017; 376(23):2235-44.